RenovoRx, headquartered in Silicon Valley, California, has developed a platform technology to deliver small molecule therapeutic agents, such as chemotherapy, to specific sites in the body. Targeted therapy via proprietary Trans-Arterial Micro-Perfusion (TAMP) safely and without transmission to non-targeted areas, is the focus of the RenovoRx technology platform. RenovoRx’s patent portfolio currently includes six US patents for its technology.
After demonstrating a median survival of approximately 28 months in Phase I/II clinical trials vs. 14-15 months reported in historical studies for this patient population, RenovoRx secured two separate Orphan Drug Designations from the FDA for Intra-Arterial gemcitabine: pancreatic cancer and bile duct cancer. This therapy is being further studied in the Phase III TIGeR-PaC trial evaluating extended median overall survival and improved quality of life for pancreatic cancer patients.
The randomized TIGeR-PaC trial is enrolling unresectable locally-advanced pancreatic cancer patients in the United States and Europe.